<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0040">
 <label>Table 14.7</label>
 <caption>
  <p>Various therapeutic proteins produced in animal cell lines.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="bottom">Cell line</th>
    <th valign="bottom">Therapeutic protein</th>
    <th valign="bottom">Potential application</th>
    <th valign="bottom">Product name</th>
    <th valign="bottom">Approval (FDA)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>CHO</td>
    <td>tPA</td>
    <td>Acute myocardial infraction</td>
    <td>Activase</td>
    <td>1987</td>
   </tr>
   <tr>
    <td>BHK</td>
    <td>Factor VIII</td>
    <td>Hemophilia A</td>
    <td>Kogenate FS</td>
    <td>1993</td>
   </tr>
   <tr>
    <td>Sp2/0</td>
    <td>Immunoglobulin GI</td>
    <td>Rheumatoid arthritis, Crohn’s disease</td>
    <td>Remicade</td>
    <td>1998</td>
   </tr>
   <tr>
    <td>BHK</td>
    <td>Factor VIIa</td>
    <td>Hemophilia A+B</td>
    <td>Novo Seven</td>
    <td>1999</td>
   </tr>
   <tr>
    <td>HEK-293</td>
    <td>Activated protein C</td>
    <td>Severe sepsis</td>
    <td>Xigris</td>
    <td>2001</td>
   </tr>
   <tr>
    <td>Hybridoma CHO</td>
    <td>Immunoglobulin G2a</td>
    <td>Non-Hodgkin’s lymphoma</td>
    <td>Bexxar</td>
    <td>2003</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Immunoglobulin GI</td>
    <td>Colorectal cancer</td>
    <td>Avastin</td>
    <td>2004</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Humanized IgG</td>
    <td>Cancer</td>
    <td>Perjeta</td>
    <td>2012</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Humanized IgG1; DM1</td>
    <td>Cancer</td>
    <td>Kadcyla</td>
    <td>2013</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Humanized IgG4κ</td>
    <td>Cancer</td>
    <td>Keytruda</td>
    <td>2014</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Human IgG4κ</td>
    <td>Cancer</td>
    <td>Opdivo</td>
    <td>2014</td>
   </tr>
   <tr>
    <td>NS0</td>
    <td>Humanized IgG1</td>
    <td>Cancer</td>
    <td>Empliciti</td>
    <td>2015</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Human IgG1κ</td>
    <td>Cancer</td>
    <td>Darzalex</td>
    <td>2015</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Humanized IgG1 Fab</td>
    <td>Hemostasis</td>
    <td>Praxbind</td>
    <td>2015</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Human IgG1</td>
    <td>Cancer</td>
    <td>Bavencio</td>
    <td>2017</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Humanized IgG1/κ</td>
    <td>Asthma</td>
    <td>Fasenra</td>
    <td>2017</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Human IgG1λ</td>
    <td>Psoriasis</td>
    <td>Tremfya</td>
    <td>2017</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Glycosylated IgG1</td>
    <td>Multiple sclerosis</td>
    <td>Ocrevus</td>
    <td>2017</td>
   </tr>
   <tr>
    <td>CHO</td>
    <td>Human recombinant IgG1</td>
    <td>Rheumatoid arthritis</td>
    <td>Kevzara</td>
    <td>2017</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
